Literature DB >> 8026877

International comparison on ras gene mutations in latent prostate carcinoma.

M Watanabe1, T Shiraishi, R Yatani, A M Nomura, G N Stemmermann.   

Abstract

Latent carcinomas of the prostate, discovered at autopsy in men with no prior treatment for prostatic disease, were studied for ras proto-oncogene mutations. Subjects included 21 Japanese, 15 U.S. whites, 15 U.S. blacks, 20 Hawaiian Japanese and 10 Colombians. PCR and sequence-specific oligonucleotide hybridization identified mutations in 5 Japanese, in 1 Hawaiian Japanese, in 1 U.S. black, in 1 U.S. white and in 3 Colombians. The 5 Japanese tumor samples contained 3 point mutations in codon 12 of K-ras and 2 mutations in codon 12 of N-ras respectively. One tumor in a Hawaiian Japanese man also showed a K-ras point mutation at codon 12. Two Colombians and one U.S. black man had tumors with mutations at codon 61 of H-ras, while 1 Colombian showed an N-ras mutation at this codon. The overall frequency of ras gene mutations was low, but point mutations in codon 12 were most common in latent tumors of Japanese, who experienced the lowest incidence and mortality from this tumor. Latent tumors in men from ethnic groups with high mortality and incidence rates showed fewer ras mutations than the Japanese, and these were more likely to involve codon 61. This finding is consistent with prior studies of more aggressive clinical cancers in Japanese men that indicated a higher frequency of mutations at codon 61.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8026877     DOI: 10.1002/ijc.2910580205

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Combined point mutations in codon 12 and 13 of KRAS oncogene in prostate carcinomas.

Authors:  Fatma Silan; Yener Gultekin; Sinem Atik; Davran Kilinc; Cabir Alan; Fazilet Yildiz; Ahmet Uludag; Ozturk Ozdemir
Journal:  Mol Biol Rep       Date:  2011-05-24       Impact factor: 2.316

2.  Bcl-2 modulation to activate apoptosis in prostate cancer.

Authors:  Kevin Bray; Hsin-Yi Chen; Cristina M Karp; Michael May; Shridar Ganesan; Vassiliki Karantza-Wadsworth; Robert S DiPaola; Eileen White
Journal:  Mol Cancer Res       Date:  2009-09-08       Impact factor: 5.852

3.  The genomic landscape of prostate cancer.

Authors:  Sylvan C Baca; Levi A Garraway
Journal:  Front Endocrinol (Lausanne)       Date:  2012-05-16       Impact factor: 5.555

4.  Interphase cytogenetics of prostate cancer: fluorescence in situ hybridisation (FISH) analysis of Japanese cases.

Authors:  H Matsuura; T Shiraishi; R Yatani; J Kawamura
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

Review 5.  Global Trends of Latent Prostate Cancer in Autopsy Studies.

Authors:  Takahiro Kimura; Shun Sato; Hiroyuki Takahashi; Shin Egawa
Journal:  Cancers (Basel)       Date:  2021-01-19       Impact factor: 6.639

6.  Microsatellite instability in human prostate cancer.

Authors:  M Watanabe; H Imai; T Shiraishi; J Shimazaki; T Kotake; R Yatani
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

Review 7.  Prostate cancer in East Asia: evolving trend over the last decade.

Authors:  Yao Zhu; Hong-Kai Wang; Yuan-Yuan Qu; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.